Key terms
About LBPH
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for neurological diseases. The company was founded on January 3, 2020 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest LBPH news
Apr 16
6:26am ET
Bexicaserin’s Promising Future: Buy Rating Justified by Strong Clinical Data and Potential Blockbuster Status
Apr 16
6:00am ET
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), Laboratory (LH) and Longboard Pharmaceuticals (LBPH)
Apr 15
9:32am ET
Longboard Pharmaceuticals to Reveal Bexicaserin Study Results
Mar 15
10:30am ET
Analysts’ Top Healthcare Picks: Longboard Pharmaceuticals (LBPH), Phathom Pharmaceuticals (PHAT)
Mar 14
2:03am ET
Longboard Pharmaceuticals Embarks on Risky Global Expansion Amid Regulatory Hurdles and Market Instability
Mar 13
5:46am ET
Buy Rating Affirmed: Longboard Pharmaceuticals’ Bexicaserin Shows Promising Efficacy and Strategic Milestones
Mar 12
4:47pm ET
Longboard Pharmaceuticals files automatic mixed securities shelf
Mar 12
4:22pm ET
Longboard Pharmaceuticals Shares Key Corporate Presentation
Mar 12
4:03pm ET
Longboard Pharmaceuticals reports FY23 EPS ($2.39), consensus ($2.40)
Feb 16
2:18pm ET
Longboard Pharmaceuticals Inc trading resumes
Feb 16
2:08pm ET
Longboard Pharmaceuticals Inc trading halted, volatility trading pause
Feb 15
4:10pm ET
Longboard Pharmaceuticals initiated with a Buy at Citi
Jan 26
8:55am ET
Longboard Pharmaceuticals 4M share Block Trade priced at $24.25
Jan 18
8:30am ET
Two new option listings and one option delisting on January 18th
No recent press releases are available for LBPH
LBPH Financials
Key terms
Ad Feedback
LBPH Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
LBPH Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range